ATE325885T1 - Methode für die produktion von adenoviralen vektoren, die nicht vom serotyp c abgeleitet sind - Google Patents

Methode für die produktion von adenoviralen vektoren, die nicht vom serotyp c abgeleitet sind

Info

Publication number
ATE325885T1
ATE325885T1 AT98923595T AT98923595T ATE325885T1 AT E325885 T1 ATE325885 T1 AT E325885T1 AT 98923595 T AT98923595 T AT 98923595T AT 98923595 T AT98923595 T AT 98923595T AT E325885 T1 ATE325885 T1 AT E325885T1
Authority
AT
Austria
Prior art keywords
serotype
derived
production
adenovirus
adenoviral vectors
Prior art date
Application number
AT98923595T
Other languages
English (en)
Inventor
Erik Falck-Pedersen
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Application granted granted Critical
Publication of ATE325885T1 publication Critical patent/ATE325885T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Electric Double-Layer Capacitors Or The Like (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AT98923595T 1997-05-22 1998-05-20 Methode für die produktion von adenoviralen vektoren, die nicht vom serotyp c abgeleitet sind ATE325885T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/861,773 US5849561A (en) 1997-05-22 1997-05-22 Method for the production of non-group C adenoviral vectors

Publications (1)

Publication Number Publication Date
ATE325885T1 true ATE325885T1 (de) 2006-06-15

Family

ID=25336722

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98923595T ATE325885T1 (de) 1997-05-22 1998-05-20 Methode für die produktion von adenoviralen vektoren, die nicht vom serotyp c abgeleitet sind

Country Status (15)

Country Link
US (1) US5849561A (de)
EP (1) EP0988389B1 (de)
JP (1) JP2001527420A (de)
AT (1) ATE325885T1 (de)
AU (1) AU743923B2 (de)
BR (1) BR9809846A (de)
CA (1) CA2289611C (de)
DE (1) DE69834489T2 (de)
HU (1) HUP0003331A3 (de)
IL (1) IL133011A0 (de)
MX (1) MXPA99010787A (de)
NZ (1) NZ500920A (de)
PL (1) PL336941A1 (de)
SK (1) SK156799A3 (de)
WO (1) WO1998053087A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
IL122614A0 (en) * 1995-06-15 1998-08-16 Introgene Bv Packaging systems for human recombinant adenovirus to be used in gene therapy
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
WO2000012740A2 (en) 1998-08-28 2000-03-09 Duke University ADENOVIRUSES DELETED IN THE IVa2, 100K AND/OR PRETERMINAL PROTEIN SEQUENCES
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
AU768836B2 (en) * 1999-04-06 2004-01-08 Advec, Inc. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
EP1170363B1 (de) * 2000-02-02 2007-11-21 Kaneda, Yasufumi VIRUS-HüLLENVEKTOR FüR GENTRANSFER
EP1157999A1 (de) * 2000-05-24 2001-11-28 Introgene B.V. Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen
WO2002024730A2 (en) * 2000-09-20 2002-03-28 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
DE60138403D1 (de) * 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
WO2003020893A2 (en) * 2001-08-30 2003-03-13 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services New adenovirus type 7 vectors
AU2003225589A1 (en) 2002-02-22 2003-09-09 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Brother of the regulator of imprinted sites (boris)
ES2335657T3 (es) * 2002-04-25 2010-03-31 Crucell Holland B.V. Medios y metodos para la produccion de vectores de adenovirus.
JP4237449B2 (ja) 2002-06-05 2009-03-11 国立医薬品食品衛生研究所長 アデノウィルスベクター
AU2003268145A1 (en) * 2002-08-22 2004-03-11 Merck And Co., Inc. Methods for propagating adenovirus and virus produced thereby
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
EP1606397A1 (de) * 2003-03-17 2005-12-21 Merck & Co., Inc. Adenovirus serotyp 24-vektoren, nukleinsäuren und so erzeugtes virus
EP1649028B1 (de) * 2003-07-25 2012-08-22 Genvec, Inc. Adenoviralevektoren-basierte impfstoffe
EP1687032B1 (de) 2003-11-14 2010-02-24 Genvec, Inc. Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
CA2880061C (en) 2004-01-23 2018-03-13 Agostino Cirillo Chimpanzee adenovirus vaccine carriers
CA2563396A1 (en) 2004-04-12 2005-11-24 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Method of using adenoviral vectors to induce an immune response
WO2006039045A2 (en) * 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
US8450055B2 (en) * 2005-08-31 2013-05-28 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
US9651543B2 (en) 2005-08-31 2017-05-16 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
US8765146B2 (en) 2005-08-31 2014-07-01 Genvec, Inc. Adenoviral vector-based malaria vaccines
BRPI0618441B8 (pt) * 2005-11-10 2021-07-27 Genvec Inc vetor adenoviral
US20080248060A1 (en) * 2007-01-09 2008-10-09 Genvec, Inc. Adenoviral vector-based malaria vaccines
WO2009149252A1 (en) * 2008-06-04 2009-12-10 Cornell University Vaccines for prevention and treatment of addiction
WO2011047316A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Nucleic acid sequences encoding expandable hiv mosaic proteins
CN102892429B (zh) 2010-03-17 2016-08-31 康奈尔大学 基于被破坏的腺病毒的抗滥用药物疫苗
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
US8920813B2 (en) 2010-12-20 2014-12-30 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
US10004811B2 (en) 2012-04-13 2018-06-26 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
EP2855511B1 (de) 2012-05-29 2019-07-24 GenVec, Inc. Impfstoff gegen das herpes-simplex virus
US10046064B2 (en) 2014-09-07 2018-08-14 Selecta Biosciences, Inc. Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
KR20240015743A (ko) 2017-01-07 2024-02-05 셀렉타 바이오사이언시즈, 인크. 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여
WO2018176103A1 (en) 2017-03-30 2018-10-04 The University Of Queensland "chimeric molecules and uses thereof"
CA3062591A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
EP4400174A2 (de) 2017-09-01 2024-07-17 The Francis Crick Institute Limited Immunregulierende moleküle und deren verwendungen
BR112020007157A2 (pt) 2017-10-13 2020-09-24 Selecta Biosciences, Inc. métodos e composições para a atenuação de respostas de igm antivetor de transferência viral
EP3735271A4 (de) 2018-01-04 2022-06-15 Iconic Therapeutics, Inc. Anti-gewebefaktor-antikörper, antikörperarzneimittel-konjugate und verwandte verfahren
CN112384204B (zh) 2018-02-26 2023-03-14 安托瑞斯公司 致耐受性脂质体及其使用方法
CN114126666A (zh) 2019-04-28 2022-03-01 西莱克塔生物科技公司 用于治疗针对病毒转移载体具有预先存在的免疫力的对象的方法
JP2022534741A (ja) 2019-05-28 2022-08-03 セレクタ バイオサイエンシーズ インコーポレーテッド 減弱化された抗ウイルス導入ベクター免疫応答のための方法および組成物
JP7457733B2 (ja) 2019-05-30 2024-03-28 グリットストーン バイオ インコーポレイテッド 改変アデノウイルス
AU2020361533A1 (en) 2019-10-08 2022-04-28 Trustees Of Boston College Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
US20230085724A1 (en) 2020-03-05 2023-03-23 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
EP0905253A3 (de) * 1992-12-03 2000-11-02 Genzyme Corporation Von allen E4-ORF ausgenommen ORF6 deletierte Adenovirus-Vector
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
ES2196018T3 (es) * 1993-08-11 2003-12-16 Wyeth Corp Vacunas de adenovirus recombinantes.
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
CA2192442C (en) * 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
WO1996009399A2 (en) * 1994-09-23 1996-03-28 Somatix Therapy Corporation Chimeric adenovirus for gene delivery
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors

Also Published As

Publication number Publication date
JP2001527420A (ja) 2001-12-25
CA2289611C (en) 2009-11-03
DE69834489T2 (de) 2006-09-07
MXPA99010787A (es) 2005-12-12
WO1998053087A1 (en) 1998-11-26
CA2289611A1 (en) 1998-11-26
BR9809846A (pt) 2000-06-20
EP0988389A1 (de) 2000-03-29
HUP0003331A2 (hu) 2001-02-28
NZ500920A (en) 2001-04-27
EP0988389B1 (de) 2006-05-10
HUP0003331A3 (en) 2003-01-28
DE69834489D1 (de) 2006-06-14
AU743923B2 (en) 2002-02-07
PL336941A1 (en) 2000-07-17
AU7584998A (en) 1998-12-11
SK156799A3 (en) 2000-05-16
US5849561A (en) 1998-12-15
IL133011A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
ATE325885T1 (de) Methode für die produktion von adenoviralen vektoren, die nicht vom serotyp c abgeleitet sind
MX9602557A (es) Proteinas de higado de mamifero y su uso en oncologia.
DE69733491D1 (de) In Krebszellen überexprimiertes Genprodukt
Burk et al. Beyond the gender gap.
Wisse The art of the possible?
Wallich Having it all.
Sudy et al. Spontaneous extracranial hemorrhagic phenomena, autoerythrocyte sensitization syndrome and anticardiolipin antibodies: Is there any relationship?
Luxner Albanian news breaks in New York.
Keenan et al. Bravo, bravo!
Green Naftathoughts for the left.
IT7926406A0 (it) Bancone, in particolare per la distribuzione di vivande.
Leonard Boundary ambiguity and coparental conflict after divorce: An empirical test of a family systems...
Faatz The independent eye.
Jaffe Responding to customers needs in linear bearings.
Dowie A sky full of holes.
Quinn Is your HMO OK--or not?
Philip Kickoff.
Cohen Russia's judgment day?
Himmelfarb Two Nations or Two Cultures?
Moyer DISCRIMINANT ANALYSES OF NEW ENGLAND MICROTUS, USING SKULL AND MOLAR MEASUREMENTS, WITH EMPHASIS ON M. BREWERI AND M. PENNSYLVANICUS (CHROTORRHINUS, PROVECTUS)
Kopitin Rossijsky Demografichesky Zhurnal.
Munk Two light guys.
Puttre CAD/CAM market continues to climb.
Farhi The Turban for the Crown/Insurgency through Culture and Religion (Book Review)
Rosenberg Gerber selling unit to Barco.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties